Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | CHIEF MEDICAL OFFICER | October 01, 2026 | October 02, 2026 |
| Verve Therapeutics, Inc.VERV · Entity 11259 | 10% owner | June 16, 2021 | June 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,059 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 1,051 · Balance 19,059 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.51 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.51 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Verve Therapeutics, Inc.
Report date June 16, 2021 · Filed June 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 409,626 |
Reported balance
Holding disclosure · report date 2021-06-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 409,626 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2025 Filed Aug 19, 2025 00:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantPerformance Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022227 · form4-08192025_120854.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-08-14 F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date. F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| August 14, 2025 Filed Aug 19, 2025 00:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022227 · form4-08192025_120854.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 4,504 | $12.82 | $57,724.16 |
DisclosureSEC source: 0001415889-25-021024 · form4-08052025_080805.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,775 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.44 to $13.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 4,503 | $11.63 | $52,379.35 |
DisclosureSEC source: 0001415889-25-019004 · form4-07022025_080730.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,279 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.31 to $11.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 00:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 6,471 | $10.03 | $64,892.48 |
DisclosureSEC source: 0001415889-25-015693 · form4-06052025_120640.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,782 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.07 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,745 | $10.00 | $17,450.00 |
DisclosureSEC source: 0001415889-25-015693 · form4-06052025_120640.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,253 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. Read SEC document |
| May 02, 2025 Filed May 5, 2025 20:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 22,790 | $10.03 | $228,542.68 |
DisclosureSEC source: 0001415889-25-011940 · form4-05052025_080547.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,998 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,841 | $10.00 | $38,410.00 |
DisclosureSEC source: 0001415889-25-011940 · form4-05052025_080547.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,788 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. Read SEC document |
| March 20, 2025 Filed Mar 20, 2025 22:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 43,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008710 · form4-03202025_100314.xml · derivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2029-03-20 F5 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The award vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 20, 2025 Filed Mar 20, 2025 22:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001415889-25-008710 · form4-03202025_100314.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2035-03-19 F4 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 22:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,333 | $8.27 | $27,563.91 |
DisclosureSEC source: 0001415889-25-008710 · form4-03202025_100314.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,629 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.06 to $8.95 per share, inclusive. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 22:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,884 | $8.67 | $33,674.28 |
DisclosureSEC source: 0001415889-25-008710 · form4-03202025_100314.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,962 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.11 to $8.925 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 3. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008359 · form4-03182025_080350.xml · derivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008359 · form4-03182025_080350.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,200 Underlying: Common Stock · 13,100 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008359 · form4-03182025_080350.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008359 · form4-03182025_080350.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:07 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,586 | $12.99 | $33,595.50 |
DisclosureSEC source: 0001415889-24-028930 · form4-12112024_091233.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,746 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 06, 2024 Filed Dec 11, 2024 00:02 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 13,945 | $12.78 | $178,182.24 |
DisclosureSEC source: 0001415889-24-028892 · form4-12112024_121235.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,332 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.93 to $13.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionPerformance Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028396 · form4-12052024_091200.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantPerformance Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028396 · form4-12052024_091200.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-12-03 F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date. F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028396 · form4-12052024_091200.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-028069 · form4-12032024_091239.xml · derivative · entry 5 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $12.07 | $120,698.00 |
DisclosureSEC source: 0001415889-24-028069 · form4-12032024_091239.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,277 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.81 to $12.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.60 | $6,000.00 |
DisclosureSEC source: 0001415889-24-028069 · form4-12032024_091239.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 48,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028069 · form4-12032024_091239.xml · derivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,981 Underlying: Common Stock · 48,792 shares Expires 2025-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: 48,792 restricted stock units vest on December 1, 2024 and 11,981 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 48,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028069 · form4-12032024_091239.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-026135 · form4-11052024_091125.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $12.68 | $126,803.00 |
DisclosureSEC source: 0001415889-24-026135 · form4-11052024_091125.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $12.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.60 | $6,000.00 |
DisclosureSEC source: 0001415889-24-026135 · form4-11052024_091125.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:07 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-024378 · form4-10022024_081008.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:07 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $12.06 | $120,648.00 |
DisclosureSEC source: 0001415889-24-024378 · form4-10022024_081008.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.63 to $12.42 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:07 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.60 | $6,000.00 |
DisclosureSEC source: 0001415889-24-024378 · form4-10022024_081008.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-022900 · form4-09052024_080953.xml · derivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 600 | $15.41 | $9,244.98 |
DisclosureSEC source: 0001415889-24-022900 · form4-09052024_080953.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.35 to $15.47 per share, inclusive. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 9,400 | $14.92 | $140,235.78 |
DisclosureSEC source: 0001415889-24-022900 · form4-09052024_080953.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,085 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.35 to $15.34 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3, below. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.60 | $6,000.00 |
DisclosureSEC source: 0001415889-24-022900 · form4-09052024_080953.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-020734 · form4-08052024_080835.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $14.58 | $145,843.00 |
DisclosureSEC source: 0001415889-24-020734 · form4-08052024_080835.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.18 to $14.94 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.60 | $6,000.00 |
DisclosureSEC source: 0001415889-24-020734 · form4-08052024_080835.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-019168 · form4-07032024_080719.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 10,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $13.75 | $137,458.00 |
DisclosureSEC source: 0001415889-24-019168 · form4-07032024_080719.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.47 to $14.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.60 | $6,000.00 |
DisclosureSEC source: 0001415889-24-019168 · form4-07032024_080719.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-015559 · form4-06052024_080649.xml · derivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 10,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 103 | $15.78 | $1,625.34 |
DisclosureSEC source: 0001415889-24-015559 · form4-06052024_080649.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 9,897 | $15.21 | $150,560.09 |
DisclosureSEC source: 0001415889-24-015559 · form4-06052024_080649.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,588 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $15.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.60 | $6,000.00 |
DisclosureSEC source: 0001415889-24-015559 · form4-06052024_080649.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-012173 · form4-05032024_080531.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 10,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $11.37 | $113,653.00 |
DisclosureSEC source: 0001415889-24-012173 · form4-05032024_080531.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.60 | $6,000.00 |
DisclosureSEC source: 0001415889-24-012173 · form4-05032024_080531.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 442 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-009999 · form4-04032024_080444.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 442 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.